Logo
x

Search category

Subscribe Now

Janssen

Janssen's Stelara (ustekinumab) Receives the US FDA's Approval for the Treatment of Active Psoriatic Arthritis in Pediatric Patients

Janssen's Stelara (ustekinumab) Receives the US FDA's Approval for the Treatment of Active Psoriatic Arthritis in Pediatric Patien...

Janssen Presents P-Ib/II (CHRYSALIS-2) Study Results of Rybrevant (amivantamab-vmjw) for Non-Small Cell Lung Cancer and EGFR Mutations at IASLC 2022

Janssen Presents P-Ib/II (CHRYSALIS-2) Study Results of Rybrevant (amivantamab-vmjw) for Non-Small Cell Lung Cancer and EGFR Mutat...

PharmaShots Interview: Daphne Chan, Head of Dermatology Medical Affairs at Janssen Shares Insights on Clinical Study in Dermatology

PharmaShots Interview: Daphne Chan, Head of Dermatology Medical Affairs at Janssen Shares Insights on Clinical Study in Dermatolog...

Janssen Presents New and Updated Results of Imbruvica (ibrutinib) in P-II (CAPTIVATE) Study as Fixed-Duration Combination Regimen for CLL and SLL at EHA 2022

Janssen Presents New and Updated Results of Imbruvica (ibrutinib) in P-II (CAPTIVATE) Study as Fixed-Duration Combination Regimen...

Janssen Reports Results of Tremfya (guselkumab) in P-III Studies Demonstrated Durable Efficacy Across Joint and Axial Symptoms for Active Psoriatic Arthritis

Janssen Reports Results of Tremfya (guselkumab) in P-III Studies Demonstrated Durable Efficacy Across Joint and Axial Symptoms for...

Janssen Presents Results of Tremfya (guselkumab) in P-II (GALAXI 1) Trial and Long-Term Safety Profile for Stelara (ustekinumab) to Treat IBD at DDW 2022

Janssen Presents Results of Tremfya (guselkumab) in P-II (GALAXI 1) Trial and Long-Term Safety Profile for Stelara (ustekinumab) t...

Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2022 PharmaShots - All Rights Reserved.